Brickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021
Brickell Biotech, Inc. (Nasdaq: BBI) announced it will report its first-quarter financial results for the period ending March 31, 2021, on May 13, 2021, after market close.
Management will host a conference call and webcast at 4:30 PM ET the same day to discuss results and corporate highlights. The company focuses on developing innovative therapeutics for skin diseases, particularly its lead asset, sofpironium bromide, for hyperhidrosis treatment.
- Conference call scheduled for May 13, 2021, for investor insights.
- Focus on innovative treatments for debilitating skin diseases.
- None.
BOULDER, Colo., April 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its financial results for the first quarter ended March 31, 2021, after the market close on Thursday, May 13, 2021. Brickell’s management will host a conference call and webcast at 4:30 pm ET on Thursday, May 13th to discuss the financial results and recent corporate highlights.
To access the call, please dial 877-705-6003 in the U.S. or 201-493-6725 outside the U.S. and provide the conference ID number: 13718897. To access the live webcast, please go to the Investors section of Brickell’s website at https://ir.brickellbio.com/events-presentations. Following the live webcast, an archived version of the call will be available on the website.
About Brickell
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs. For more information, visit https://www.brickellbio.com.
Brickell Investor Contact:
Dan Ferry
LifeSci Advisors
(617) 430-7576
daniel@lifesciadvisors.com
FAQ
When will Brickell Biotech report its Q1 2021 financial results?
What is the focus of Brickell Biotech's product development?
What time is the Brickell Biotech conference call on May 13, 2021?
What is Brickell Biotech's lead asset?
